Using a Tailored Digital Health Intervention for Family Communication and Cascade Genetic Testing in Swiss and Korean Families With Hereditary Breast and Ovarian Cancer: Protocol for the DIALOGUE Study

Sue Kim, Monica Aceti, Vasiliki Baroutsou, Nicole Bürki, Maria Caiata-Zufferey, Marco Cattaneo, Pierre O Chappuis, Florina M Ciorba, Rossella Graffeo-Galbiati, Viola Heinzelmann-Schwarz, Joon Jeong, MiSook M Jung, Sung-Won Kim, Jisun Kim, Myong Cheol Lim, Chang Ming, Christian Monnerat, Hyung Seok Park, Sang Hyung Park, Carla A Pedrazzani, Manuela Rabaglio, Jai Min Ryu, Ramon Saccilotto, Simon Wieser, Ursina Zürrer-Härdi, Maria C Katapodi, Sue Kim, Monica Aceti, Vasiliki Baroutsou, Nicole Bürki, Maria Caiata-Zufferey, Marco Cattaneo, Pierre O Chappuis, Florina M Ciorba, Rossella Graffeo-Galbiati, Viola Heinzelmann-Schwarz, Joon Jeong, MiSook M Jung, Sung-Won Kim, Jisun Kim, Myong Cheol Lim, Chang Ming, Christian Monnerat, Hyung Seok Park, Sang Hyung Park, Carla A Pedrazzani, Manuela Rabaglio, Jai Min Ryu, Ramon Saccilotto, Simon Wieser, Ursina Zürrer-Härdi, Maria C Katapodi

Abstract

Background: In hereditary breast and ovarian cancer (HBOC), family communication of genetic test results is essential for cascade genetic screening, that is, identifying and testing blood relatives of known mutation carriers to determine whether they also carry the pathogenic variant, and to propose preventive and clinical management options. However, up to 50% of blood relatives are unaware of relevant genetic information, suggesting that potential benefits of genetic testing are not communicated effectively within family networks. Technology can facilitate communication and genetic education within HBOC families.

Objective: The aims of this study are to develop the K-CASCADE (Korean-Cancer Predisposition Cascade Genetic Testing) cohort in Korea by expanding an infrastructure developed by the CASCADE (Cancer Predisposition Cascade Genetic Testing) Consortium in Switzerland; develop a digital health intervention to support the communication of cancer predisposition for Swiss and Korean HBOC families, based on linguistic and cultural adaptation of the Family Gene Toolkit; evaluate its efficacy on primary (family communication of genetic results and cascade testing) and secondary (psychological distress, genetic literacy, active coping, and decision making) outcomes; and explore its translatability using the reach, effectiveness, adoption, implementation, and maintenance framework.

Methods: The digital health intervention will be available in French, German, Italian, Korean, and English and can be accessed via the web, mobile phone, or tablet (ie, device-agnostic). K-CASCADE cohort of Korean HBOC mutation carriers and relatives will be based on the CASCADE infrastructure. Narrative data collected through individual interviews or mini focus groups from 20 to 24 HBOC family members per linguistic region and 6-10 health care providers involved in genetic services will identify the local cultures and context, and inform the content of the tailored messages. The efficacy of the digital health intervention against a comparison website will be assessed in a randomized trial with 104 HBOC mutation carriers (52 in each study arm). The translatability of the digital health intervention will be assessed using survey data collected from HBOC families and health care providers.

Results: Funding was received in October 2019. It is projected that data collection will be completed by January 2023 and results will be published in fall 2023.

Conclusions: This study addresses the continuum of translational research, from developing an international research infrastructure and adapting an existing digital health intervention to testing its efficacy in a randomized controlled trial and exploring its translatability using an established framework. Adapting existing interventions, rather than developing new ones, takes advantage of previous valid experiences without duplicating efforts. Culturally sensitive web-based interventions that enhance family communication and understanding of genetic cancer risk are timely. This collaboration creates a research infrastructure between Switzerland and Korea that can be scaled up to cover other hereditary cancer syndromes.

Trial registration: ClinicalTrials.gov NCT04214210; https://ichgcp.net/clinical-trials-registry/NCT04214210 and CRiS KCT0005643; https://cris.nih.go.kr/cris/.

International registered report identifier (irrid): PRR1-10.2196/26264.

Keywords: HBOC; RE-AIM; communicating; coping; cultural and linguistic adaptation; decisional conflict; implementation; mobile phone; proportion of informed at-risk relatives.

Conflict of interest statement

Conflicts of Interest: None declared.

©Sue Kim, Monica Aceti, Vasiliki Baroutsou, Nicole Bürki, Maria Caiata-Zufferey, Marco Cattaneo, Pierre O Chappuis, Florina M Ciorba, Rossella Graffeo-Galbiati, Viola Heinzelmann-Schwarz, Joon Jeong, MiSook M Jung, Sung-Won Kim, Jisun Kim, Myong Cheol Lim, Chang Ming, Christian Monnerat, Hyung Seok Park, Sang Hyung Park, Carla A Pedrazzani, Manuela Rabaglio, Jai Min Ryu, Ramon Saccilotto, Simon Wieser, Ursina Zürrer-Härdi, Maria C Katapodi. Originally published in JMIR Research Protocols (https://www.researchprotocols.org), 11.06.2021.

Figures

Figure 1
Figure 1
Examples from the Family Gene Toolkit.

References

    1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh J, Comber H, Forman D, Bray F. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013 Apr;49(6):1374–403. doi: 10.1016/j.ejca.2012.12.027.
    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394–424. doi: 10.3322/caac.21492. doi: 10.3322/caac.21492.
    1. DeSantis CE, Ma J, Gaudet MM, Newman LA, Miller KD, Goding Sauer A, Jemal A, Siegel RL. Breast cancer statistics, 2019. CA Cancer J Clin. 2019 Nov;69(6):438–51. doi: 10.3322/caac.21583. doi: 10.3322/caac.21583.
    1. Sopik V. International variation in breast cancer incidence and mortality in young women. Breast Cancer Res Treat. 2021 Apr;186(2):497–507. doi: 10.1007/s10549-020-06003-8.
    1. Yip CH, Evans DG, Agarwal G, Buccimazza I, Kwong A, Morant R, Prakash I, Song CY, Taib NA, Tausch C, Ung O, Meterissian S. Global disparities in breast cancer genetics testing, counselling and management. World J Surg. 2019 May 4;43(5):1264–70. doi: 10.1007/s00268-018-04897-6.
    1. Park EH, Min SY, Kim Z, Yoon CS, Jung K, Nam SJ, Oh SJ, Lee S, Park B, Lim W, Hur MH, Korean Breast Cancer Society Basic facts of breast cancer in Korea in 2014: the 10-year overall survival progress. J Breast Cancer. 2017 Mar;20(1):1–11. doi: 10.4048/jbc.2017.20.1.1.
    1. Park B, Hopper JL, Win AK, Dowty JG, Sung HK, Ahn C, Kim S, Lee MH, Lee J, Lee JW, Kang E, Yu J, Kim KS, Moon B, Han W, Noh D, Park SK, KOHBRA Study Group Reproductive factors as risk modifiers of breast cancer in mutation carriers and high-risk non-carriers. Oncotarget. 2017 Nov 24;8(60):102110–8. doi: 10.18632/oncotarget.22193.
    1. Schoumacher F, Glaus A, Mueller H, Eppenberger U, Bolliger B, Senn H. BRCA1/2 mutations in Swiss patients with familial or early-onset breast and ovarian cancer. Swiss Med Wkly. 2001. Apr 21, [2021-05-06].
    1. Greenberg S, Buys SS, Edwards SL, Espinel W, Fraser A, Gammon A, Hafen B, Herget KA, Kohlmann W, Roundy C, Sweeney C. Population prevalence of individuals meeting criteria for hereditary breast and ovarian cancer testing. Cancer Med. 2019 Nov;8(15):6789–98. doi: 10.1002/cam4.2534. doi: 10.1002/cam4.2534.
    1. Grosse SD, Rogowski WH, Ross LF, Cornel MC, Dondorp WJ, Khoury MJ. Population screening for genetic disorders in the 21st century: evidence, economics, and ethics. Public Health Genomics. 2010;13(2):106–15. doi: 10.1159/000226594.
    1. Clain E, Trosman JR, Douglas MP, Weldon CB, Phillips KA. Availability and payer coverage of BRCA1/2 tests and gene panels. Nat Biotechnol. 2015 Sep;33(9):900–2. doi: 10.1038/nbt.3322.
    1. Katz SJ, Kurian AW, Morrow M. Treatment decision making and genetic testing for breast cancer: mainstreaming mutations. J Am Med Assoc. 2015 Sep 08;314(10):997–8. doi: 10.1001/jama.2015.8088.
    1. Khoury MJ, Evans JP. A public health perspective on a national precision medicine cohort: balancing long-term knowledge generation with early health benefit. J Am Med Assoc. 2015 Jun 02;313(21):2117–8. doi: 10.1001/jama.2015.3382.
    1. Katapodi MC, Viassolo V, Caiata-Zufferey M, Nikolaidis C, Bührer-Landolt R, Buerki N, Graffeo R, Horváth HC, Kurzeder C, Rabaglio M, Scharfe M, Urech C, Erlanger TE, Probst-Hensch N, Heinimann K, Heinzelmann-Schwarz V, Pagani O, Chappuis PO. Cancer predisposition cascade screening for hereditary breast/ovarian cancer and lynch syndromes in Switzerland: study protocol. JMIR Res Protoc. 2017 Sep 20;6(9):e184. doi: 10.2196/resprot.8138.
    1. Nikolaidis C, Ming C, Pedrazzani C, van der Horst T, Kaiser-Grolimund A, Ademi Z, Bührer-Landolt R, Bürki N, Caiata-Zufferey M, Champion V, Chappuis PO, Kohler C, Erlanger TE, Graffeo R, Hampel H, Heinimann K, Heinzelmann-Schwarz V, Kurzeder C, Monnerat C, Northouse LL, Pagani O, Probst-Hensch N, Rabaglio M, Schoenau E, Sijbrands EJ, Taborelli M, Urech C, Viassolo V, Wieser S, Katapodi MC, for the CASCADE Consortium Challenges and opportunities for cancer predisposition cascade screening for hereditary breast and ovarian cancer and lynch syndrome in Switzerland: findings from an international workshop. Public Health Genomics. 2018;21(3-4):121–32. doi: 10.1159/000496495.
    1. Kang E, Park SK, Lee JW, Kim Z, Noh W, Jung Y, Yang J, Jung SH, Kim S. KOHBRA BRCA risk calculator (KOHCal): a model for predicting BRCA1 and BRCA2 mutations in Korean breast cancer patients. J Hum Genet. 2016 May;61(5):365–71. doi: 10.1038/jhg.2015.164.
    1. Kang E, Seong M, Park SK, Lee JW, Lee J, Kim LS, Lee JE, Kim SY, Jeong J, Han SA, Kim S, Korean Hereditary Breast Cancer Study Group The prevalence and spectrum of BRCA1 and BRCA2 mutations in Korean population: recent update of the Korean Hereditary Breast Cancer (KOHBRA) study. Breast Cancer Res Treat. 2015 May;151(1):157–68. doi: 10.1007/s10549-015-3377-4.
    1. Caiata-Zufferey M, Pagani O, Cina V, Membrez V, Taborelli M, Unger S, Murphy A, Monnerat C, Chappuis PO. Challenges in managing genetic cancer risk: a long-term qualitative study of unaffected women carrying BRCA1/BRCA2 mutations. Genet Med. 2015 Sep;17(9):726–32. doi: 10.1038/gim.2014.183.
    1. Fadda M, Chappuis PO, Katapodi MC, Pagani O, Monnerat C, Membrez V, Unger S, Caiata Zufferey M. Physicians communicating with women at genetic risk of breast and ovarian cancer: are we in the middle of the ford between contradictory messages and unshared decision making? PLoS One. 2020;15(10):e0240054. doi: 10.1371/journal.pone.0240054.
    1. Kim H, Kim SY, Joly Y. South Korea: in the midst of a privacy reform centered on data sharing. Hum Genet. 2018 Aug;137(8):627–35. doi: 10.1007/s00439-018-1920-1.
    1. Caswell-Jin JL, Gupta T, Hall E, Petrovchich IM, Mills MA, Kingham KE, Koff R, Chun NM, Levonian P, Lebensohn AP, Ford JM, Kurian AW. Racial/ethnic differences in multiple-gene sequencing results for hereditary cancer risk. Genet Med. 2018 Feb;20(2):234–9. doi: 10.1038/gim.2017.96.
    1. Fraser L, Bramald S, Chapman C, Chu C, Cornelius V, Douglas F, Lucassen A, Nehammer A, Sutton S, Trivella M, Hodgson S. What motivates interest in attending a familial cancer genetics clinic? Familial Cancer. 2001;2(3/4):159–68. doi: 10.1023/b:fame.0000004621.38109.16.
    1. Kang E, Park SK, Kim KS, Choi DH, Nam S, Paik NS, Lee JW, Lee MH, Kim S, Society KB. Communication with family members about positive BRCA1/2 genetic test results in Korean hereditary breast cancer families. J Genet Med. 2011 Dec 31;8(2):105–12. doi: 10.5734/jgm.2011.8.2.105.
    1. van den Heuvel LM, Stemkens D, van Zelst-Stams WA, Willeboordse F, Christiaans I. How to inform at-risk relatives? Attitudes of 1379 Dutch patients, relatives, and members of the general population. J Genet Couns. 2020 Oct;29(5):786–99. doi: 10.1002/jgc4.1206.
    1. Ratnayake P, Wakefield CE, Meiser B, Suthers G, Price MA, Duffy J, Kathleen Cuningham National Consortium for Research into Familial Breast Cancer. Tucker K. An exploration of the communication preferences regarding genetic testing in individuals from families with identified breast/ovarian cancer mutations. Fam Cancer. 2011 Mar;10(1):97–105. doi: 10.1007/s10689-010-9383-0.
    1. Bowen DJ, Hyams T, Laurino M, Woolley T, Cohen S, Leppig KA, Jarvik G. Development of Familytalk: an intervention to support communication and educate families about colorectal cancer risk. J Cancer Educ. 2020 Jun;35(3):470–8. doi: 10.1007/s13187-019-1484-3.
    1. Birch PH. Interactive e-counselling for genetics pre-test decisions: where are we now? Clin Genet. 2015 Mar;87(3):209–17. doi: 10.1111/cge.12430.
    1. Syrowatka A, Krömker D, Meguerditchian AN, Tamblyn R. Features of computer-based decision aids: systematic review, thematic synthesis, and meta-analyses. J Med Internet Res. 2016 Jan 26;18(1):e20. doi: 10.2196/jmir.4982.
    1. Vrečar I, Hristovski D, Peterlin B. Telegenetics: an update on availability and use of telemedicine in clinical genetics service. J Med Syst. 2017 Feb;41(2):21. doi: 10.1007/s10916-016-0666-3.
    1. Otten E, Birnie E, Ranchor AV, van Langen IM. Telegenetics use in presymptomatic genetic counselling: patient evaluations on satisfaction and quality of care. Eur J Hum Genet. 2016 Apr;24(4):513–20. doi: 10.1038/ejhg.2015.164.
    1. Buchanan AH, Datta SK, Skinner CS, Hollowell GP, Beresford HF, Freeland T, Rogers B, Boling J, Marcom PK, Adams MB. Randomized trial of telegenetics vs. In-person cancer genetic counseling: cost, patient satisfaction and attendance. J Genet Couns. 2015 Dec;24(6):961–70. doi: 10.1007/s10897-015-9836-6.
    1. Gaieski JB, Patrick-Miller L, Egleston BL, Maxwell KN, Walser S, DiGiovanni L, Brower J, Fetzer D, Ganzak A, McKenna D, Long JM, Powers J, Stopfer JE, Nathanson KL, Domchek SM, Bradbury AR. Research participants' experiences with return of genetic research results and preferences for web-based alternatives. Mol Genet Genomic Med. 2019 Sep;7(9):e898. doi: 10.1002/mgg3.898. doi: 10.1002/mgg3.898.
    1. Katapodi MC, Jung M, Schafenacker AM, Milliron KJ, Mendelsohn-Victor KE, Merajver SD, Northouse LL. Development of a web-based family intervention for BRCA carriers and their biological relatives: acceptability, feasibility, and usability study. JMIR Cancer. 2018 Apr 13;4(1):e7. doi: 10.2196/cancer.9210.
    1. Battaglia C, Glasgow RE. Pragmatic dissemination and implementation research models, methods and measures and their relevance for nursing research. Nurs Outlook. 2018 Sep;66(5):430–45. doi: 10.1016/j.outlook.2018.06.007.
    1. Curran GM, Bauer M, Mittman B, Pyne JM, Stetler C. Effectiveness-implementation hybrid designs: combining elements of clinical effectiveness and implementation research to enhance public health impact. Med Care. 2012 Mar;50(3):217–26. doi: 10.1097/MLR.0b013e3182408812.
    1. Folkman S, Moskowitz JT. Stress, appraisal, and coping. In: Anderson NB, editor. Encyclopedia of Health and Behavior. Thousand Oaks, California, United States: Sage Publications Inc; 2004. pp. 1927–35.
    1. Katapodi MC, Dodd MJ, Lee KA, Facione NC. Underestimation of breast cancer risk: influence on screening behavior. Oncol Nurs Forum. 2009 May;36(3):306–14. doi: 10.1188/09.ONF.306-314.
    1. Katapodi MC, Lee KA, Facione NC, Dodd MJ. Predictors of perceived breast cancer risk and the relation between perceived risk and breast cancer screening: a meta-analytic review. Prev Med. 2004 Apr;38(4):388–402. doi: 10.1016/j.ypmed.2003.11.012.
    1. Katapodi MC, Northouse LL, Milliron KJ, Liu G, Merajver SD. Individual and family characteristics associated with BRCA1/2 genetic testing in high-risk families. Psychooncology. 2013 Jun;22(6):1336–43. doi: 10.1002/pon.3139.
    1. Northouse LL, Katapodi MC, Song L, Zhang L, Mood DW. Interventions with family caregivers of cancer patients: meta-analysis of randomized trials. CA Cancer J Clin. 2010;60(5):317–39. doi: 10.3322/caac.20081. doi: 10.3322/caac.20081.
    1. Northouse L, Schafenacker A, Barr KL, Katapodi M, Yoon H, Brittain K, Song L, Ronis DL, An L. A tailored Web-based psychoeducational intervention for cancer patients and their family caregivers. Cancer Nurs. 2014;37(5):321–30. doi: 10.1097/NCC.0000000000000159.
    1. Barry MJ, Edgman-Levitan S. Shared decision making--pinnacle of patient-centered care. N Engl J Med. 2012 Mar 01;366(9):780–1. doi: 10.1056/NEJMp1109283.
    1. Kohler JN, Turbitt E, Biesecker BB. Personal utility in genomic testing: a systematic literature review. Eur J Hum Genet. 2017 Jun;25(6):662–8. doi: 10.1038/ejhg.2017.10.
    1. Daly MB, Pilarski R, Berry M, Buys SS, Farmer M, Friedman S, Garber JE, Kauff ND, Khan S, Klein C, Kohlmann W, Kurian A, Litton JK, Madlensky L, Merajver SD, Offit K, Pal T, Reiser G, Shannon KM, Swisher E, Vinayak S, Voian NC, Weitzel JN, Wick MJ, Wiesner GL, Dwyer M, Darlow S. NCCN guidelines insights: genetic/familial high-risk assessment: breast and ovarian, version 2. J Natl Compr Canc Netw. 2017 Jan;15(1):9–20. doi: 10.6004/jnccn.2017.0003.
    1. Hawkins RP, Kreuter M, Resnicow K, Fishbein M, Dijkstra A. Understanding tailoring in communicating about health. Health Educ Res. 2008 Jun 01;23(3):454–66. doi: 10.1093/her/cyn004.
    1. Kreuter MW, Wray RJ. Tailored and targeted health communication: strategies for enhancing information relevance. Am J Health Behav. 2003;27 Suppl 3:227–32. doi: 10.5993/ajhb.27.1.s3.6.
    1. Kushniruk AW, Patel VL. Cognitive and usability engineering methods for the evaluation of clinical information systems. J Biomed Inform. 2004 Feb;37(1):56–76. doi: 10.1016/j.jbi.2004.01.003.
    1. Glasgow RE, Fisher L, Strycker LA, Hessler D, Toobert DJ, King DK, Jacobs T. Minimal intervention needed for change: definition, use, and value for improving health and health research. Transl Behav Med. 2014 Mar;4(1):26–33. doi: 10.1007/s13142-013-0232-1.
    1. Empowering families with hereditary cancers through communication and education. Kintalk. [2020-07-11].
    1. Katapodi MC, Ming C, Northouse LL, Duffy SA, Duquette D, Mendelsohn-Victor KE, Milliron KJ, Merajver SD, Dinov ID, Janz NK. Genetic testing and surveillance of young breast cancer survivors and blood relatives: a cluster randomized trial. Cancers (Basel) 2020 Sep 05;12(9):2526. doi: 10.3390/cancers12092526.
    1. RE-AIM framework. [2020-11-05].
    1. Bastien JM. Usability testing: a review of some methodological and technical aspects of the method. Int J Med Inform. 2010 Apr;79(4):18–23. doi: 10.1016/j.ijmedinf.2008.12.004.
    1. Nielsen J. Usability Engineering. Burlington, Massachusetts, United States: Morgan Kaufmann; 1994. pp. 1–362.
    1. Katapodi MC, Duquette D, Yang JJ, Mendelsohn-Victor K, Anderson B, Nikolaidis C, Mancewicz E, Northouse LL, Duffy S, Ronis D, Milliron KJ, Probst-Herbst N, Merajver SD, Janz NK, Copeland G, Roberts S. Recruiting families at risk for hereditary breast and ovarian cancer from a statewide cancer registry: a methodological study. Cancer Causes Control. 2017 Mar;28(3):191–201. doi: 10.1007/s10552-017-0858-2.
    1. Behavioral risk factor surveillance system questionnaire. Centers for Disease Control and Prevention. 2001. [2019-01-18]. .
    1. Vickberg SMJ. The Concerns About Recurrence Scale (CARS): a systematic measure of women's fears about the possibility of breast cancer recurrence. Ann Behav Med. 2003;25(1):16–24. doi: 10.1207/S15324796ABM2501_03.
    1. Champion VL, Ziner KW, Monahan PO, Stump TE, Cella D, Smith LG, Bell CJ, Von Ah D, Sledge GW. Development and psychometric testing of a breast cancer survivor self-efficacy scale. Oncol Nurs Forum. 2013 Nov;40(6):403–10. doi: 10.1188/13.ONF.E403-E410.
    1. Katapodi MC, Facione NC, Miaskowski C, Dodd MJ, Waters C. The influence of social support on breast cancer screening in a multicultural community sample. Oncol Nurs Forum. 2002 Jun;29(5):845–52. doi: 10.1188/02.ONF.845-852.
    1. McCubbin HI, Thompson AI, McCubbin MA. Family Assessment: Resiliency, Coping and Adaptation (Inventories for Research and Practice) Madison: University of Wisconsin, Center for Excellence in Family Studies; 1996. pp. 1–912.
    1. Cella D, Hughes C, Peterman A, Chang C, Peshkin BN, Schwartz MD, Wenzel L, Lemke A, Marcus AC, Lerman C. A brief assessment of concerns associated with genetic testing for cancer: the Multidimensional Impact of Cancer Risk Assessment (MICRA) questionnaire. Health Psychol. 2002 Nov;21(6):564–72.
    1. Anderson B, McLosky J, Wasilevich E, Lyon-Callo S, Duquette D, Copeland G. Barriers and facilitators for utilization of genetic counseling and risk assessment services in young female breast cancer survivors. J Cancer Epidemiol. 2012;2012:298745. doi: 10.1155/2012/298745. doi: 10.1155/2012/298745.
    1. Durand M, Witt J, Joseph-Williams N, Newcombe RG, Politi MC, Sivell S, Elwyn G. Minimum standards for the certification of patient decision support interventions: feasibility and application. Patient Educ Couns. 2015 Apr;98(4):462–8. doi: 10.1016/j.pec.2014.12.009.
    1. Hoffman AS, Llewellyn-Thomas HA, Tosteson AN, O'Connor AM, Volk RJ, Tomek IM, Andrews SB, Bartels SJ. Launching a virtual decision lab: development and field-testing of a web-based patient decision support research platform. BMC Med Inform Decis Mak. 2014 Dec 12;14:112. doi: 10.1186/s12911-014-0112-8.
    1. de Geus E, Aalfs CM, Menko FH, Sijmons RH, Verdam MG, de Haes HC, Smets EM. Development of the Informing Relatives Inventory (IRI): assessing index patients' knowledge, motivation and self-efficacy regarding the disclosure of hereditary cancer risk information to relatives. Int J Behav Med. 2015 Aug;22(4):551–60. doi: 10.1007/s12529-014-9455-x.
    1. Curran SL, Andrykowski MA, Studts JL. Short Form of the Profile of Mood States (POMS-SF): psychometric information. Psychol Assess. 1995;7(1):80–3. doi: 10.1037/1040-3590.7.1.80.
    1. Wang C, Gonzalez R, Milliron KJ, Strecher VJ, Merajver SD. Genetic counseling for BRCA1/2: a randomized controlled trial of two strategies to facilitate the education and counseling process. Am J Med Genet A. 2005 Apr 01;134A(1):66–73. doi: 10.1002/ajmg.a.30577.
    1. Carver CS. You want to measure coping but your protocol's too long: consider the brief COPE. Int J Behav Med. 1997;4(1):92–100. doi: 10.1207/s15327558ijbm0401_6.
    1. Katapodi M, Munro M, Pierce P, Williams R. Psychometric testing of the decisional conflict scale genetic testing hereditary breast and ovarian cancer. Nurse Res. 2011;60(6):368–77. doi: 10.1097/nnr.0b013e3182337dad.
    1. Brehaut JC, O'Connor AM, Wood TJ, Hack TF, Siminoff L, Gordon E, Feldman-Stewart D. Validation of a decision regret scale. Med Decis Making. 2003;23(4):281–92. doi: 10.1177/0272989X03256005.
    1. Northouse LL, Walker J, Schafenacker A, Mood D, Mellon S, Galvin E, Harden J, Freeman-Gibb L. A family-based program of care for women with recurrent breast cancer and their family members. Oncol Nurs Forum. 2002;29(10):1411–9. doi: 10.1188/02.ONF.1411-1419.
    1. R-4.0.5 for Windows (32/64 bit) [2020-11-07].
    1. Claes E, Evers-Kiebooms G, Boogaerts A, Decruyenaere M, Denayer L, Legius E. Communication with close and distant relatives in the context of genetic testing for hereditary breast and ovarian cancer in cancer patients. Am J Med Genet A. 2003 Jan 01;116A(1):11–9. doi: 10.1002/ajmg.a.10868.
    1. Kenen R, Arden-Jones A, Eeles R. We are talking, but are they listening? Communication patterns in families with a history of breast/ovarian cancer (HBOC) Psychooncology. 2004 May;13(5):335–45. doi: 10.1002/pon.745.
    1. Nycum G, Avard D, Knoppers BM. Factors influencing intrafamilial communication of hereditary breast and ovarian cancer genetic information. Eur J Hum Genet. 2009 Jul 25;17(7):872–80. doi: 10.1038/ejhg.2009.33.
    1. George R, Kovak K, Cox SL. Aligning policy to promote cascade genetic screening for prevention and early diagnosis of heritable diseases. J Genet Couns. 2015 Jun;24(3):388–99. doi: 10.1007/s10897-014-9805-5.
    1. Modell S, Greendale K, Citrin T, Kardia S. Expert and advocacy group consensus findings on the horizon of public health genetic testing. Healthcare (Basel) 2016 Jan 27;4(1):14. doi: 10.3390/healthcare4010014.
    1. Walker JL, Powell CB, Chen L, Carter J, Bae Jump VL, Parker LP, Borowsky ME, Gibb RK. Society of Gynecologic Oncology recommendations for the prevention of ovarian cancer. Cancer. 2015 Jul 01;121(13):2108–20. doi: 10.1002/cncr.29321. doi: 10.1002/cncr.29321.
    1. Burke NJ, Mathews HF. Returning to earth: setting a global agenda for the anthropology of cancer. Med Anthropol. 2017 Apr;36(3):179–86. doi: 10.1080/01459740.2016.1255611.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever